Important note

This AI stock analysis for ProPhase Labs is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

ProPhase Labs - AI Stock Analysis

Analysis generated December 3, 2024

ProPhase Labs is a company engaged in the development, manufacturing, and marketing of over-the-counter consumer healthcare products. Known for its focus on quality health aids and dietary supplements, the company has a diverse portfolio that caters to various consumer needs. ProPhase Labs has established itself in a competitive market but faces the challenge of maintaining and growing its market share.

Fundamental Analysis

When assessing ProPhase Labs' fundamentals, several key metrics stand out. Revenue for the last quarter was $3.1M, representing a robust growth of 27.16% compared to the previous quarter. This positive quarterly growth is a promising sign for the company. However, it is crucial to note the revenue was down by 61.11% compared to the same quarter last year, which is alarming and suggests potential operational or market challenges.

Net income for the last quarter was $6.6M, a decrease of 7.05% compared to the quarter before it. This decline suggests there may be some underlying issues affecting profitability. Compared to the same quarter last year, net income was down by 28.13%, which is a significant drop and could indicate broader financial instability.

EBITDA for the last quarter was $7M, an increase of 1.25% from the previous quarter, which is a positive indicator of growth. However, compared to the same quarter last year, EBITDA saw a significant decline of 76.54%, which raises concerns about the company's longer-term performance and operational efficiency.

Technical Analysis

Today's stock price is $0.79, representing a dramatic decrease of 63.08% compared to a month ago. This short-term decline could be unsettling for investors. Moreover, the price has decreased by 83.71% compared to a year ago, raising serious concerns for long-term investors.

However, the technical trend shows a bullish sentiment. The current Simple Moving Average (SMA10) is $0.77, which is higher than the previous SMA10 of $0.77. This slight improvement indicates a potential upward trend in price movement. Additionally, the Relative Strength Index (RSI) is 38.6, which signals a neutral condition, providing neither a strong buy nor sell signal.

Alternative Data Analysis

Alternative data provides a different perspective on ProPhase Labs' performance and potential. Notably, job postings and employee sentiment can serve as indicators of internal health. A decrease in the number of job postings or negative employee sentiment might suggest issues within the company.

The estimated number of visitors to ProPhase Labs' webpage is around 1,000, a decline of 50% over the past couple of months. This trend is concerning as it could indicate a loss in customer interest and potential revenue.

Moreover, AltIndex's AI score for ProPhase Labs is 47, which signals a "Hold." This score considers various fundamental, technical, and alternative data points, suggesting that while there is no strong impetus to sell, there may not be enough positive indicators to justify a buy either.

Conclusion and Recommendation

ProPhase Labs presents a mixed bag of indicators for potential investors. While the revenue growth in the last quarter is promising, the considerable year-over-year declines in revenue, net income, and EBITDA are concerning. The stock's recent price performance has been poor, although there are some technical signs of potential recovery.

Alternative data further complicates the picture, with declining web traffic suggesting potential issues in customer acquisition and retention. The AI score of 47 implies that holding the stock might be the most prudent course of action for now.

Given the current data, it is recommended to adopt a cautious approach. Investors should consider holding their position and closely monitor upcoming quarterly results and market conditions. This will help in making more informed decisions in the near future.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.